Company Overview of Profectus Biosciences, Inc.
Profectus Biosciences, Inc., a technology based vaccine company, engages in the treatment and prevention of chronic viral diseases. It offers vaccine products to address diseases caused by hepatitis C virus, human immunodeficiency virus, human papilloma virus, and herpes simplex virus, as well as for malaria. The company was formerly known as Maryland Biotherapeutics and changed its name to Profectus Biosciences, Inc. in 2004. Profectus Biosciences, Inc. was founded in 2003 and is based in Baltimore, Maryland with an additional office in Tarrytown, New York.
6411 Beckley Street
Baltimore, MD 21224
Founded in 2003
Key Executives for Profectus Biosciences, Inc.
Chief Executive Officer and President
Chief Operating Officer and Vice President of Business Development
Chief Scientific Officer of Vaccines
Senior Director of Virology
Compensation as of Fiscal Year 2014.
Profectus Biosciences, Inc. Key Developments
Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
Profectus Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Profectus BioSciences, Inc. Receives $8.6 Million HHS Contract to Accelerate Ebola Vaccine into Human Clinical Studies
Oct 22 14
Profectus BioSciences, Inc. announced that the company has received a contract from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) aimed at accelerating the advancement of the company's candidate Ebola vaccine into human clinical studies. In previous preclinical studies conducted in collaboration with the National Institutes of Health (NIH) and Department of Defense (DoD) in non-human primates, a single dose of the Profectus vaccine has been shown to provide 100% protection against Ebola Zaire. The one-year contract with the ASPR's Biomedical Advanced Research and Development Authority (BARDA) will provide $5.8 million in funding to conduct toxicology studies to evaluate the safety of the company's novel VesiculoVax(TM) Ebola vaccine candidate and to manufacture the vaccine for use in Phase 1 clinical studies. The contract can be extended to a total of 13 months and $8.6 million. Upon successful completion of these initiatives, Profectus will apply to the U.S. Food and Drug Administration for an Investigational New Drug (IND) designation that would allow initiation of human clinical trials to evaluate the vaccine's safety and immunogenicity in humans. With this most recent funding, Profectus has secured a total of $27.9 million to develop the VesiculoVax(TM) Ebola vaccine, including: HHS, October 2014: $8.6 million; DoD, October 2014: $8.5 million; NIAID, March 2014: $5.4 million; and NIAID, May 2012: $5.4 million.
Profectus Biosciences Wins Federal Contract for 'Research and Development of the rVSVN4CT1 Vaccine'
Oct 15 14
Office of the Secretary (Department of Health and Human Services), Acquisitions Management, Contracts, & Grants (AMCG), has awarded a $8,620,131.00 federal contract on Oct. 14 for 'Research and Development of the rVSVN4CT1 vaccine'. Contractor Awardee was Profectus BioSciences Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|